The significance of cytomegalovirus viremia at day 100 or more following allogeneic hematopoietic stem cell transplantation
暂无分享,去创建一个
[1] M. Boeckh,et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. , 2010, Blood.
[2] B. Sandmaier,et al. Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] N. Mahmud,et al. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? , 2008, Bone Marrow Transplantation.
[4] H. Nakasone,et al. Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation , 2008, International journal of hematology.
[5] P. Ljungman,et al. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival , 2008, Bone Marrow Transplantation.
[6] M. Labopin,et al. Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation , 2007, Bone Marrow Transplantation.
[7] P. Ljungman,et al. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT , 2007, Bone Marrow Transplantation.
[8] E. Shpall,et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies , 2007, Bone Marrow Transplantation.
[9] N. Mahmud,et al. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation , 2006, Bone Marrow Transplantation.
[10] D. Follmann,et al. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[11] G. Papanicolaou,et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] W. Leisenring,et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. , 2002, Blood.
[13] S. Rowland-Jones,et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. , 2002, Blood.
[14] P. Griffiths,et al. Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] A. Verma,et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. , 2002, Blood.
[16] M. Boeckh,et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. , 2002, The Journal of infectious diseases.
[17] J. Mary,et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients , 2001, British journal of haematology.
[18] C. Pannuti,et al. Extended antigenemia surveillance and late cytomegalovirus infection after allogeneic BMT , 2001, Bone Marrow Transplantation.
[19] R. Tedder,et al. Extended routine polymerase chain reaction surveillance and pre‐emptive antiviral therapy for cytomegalovirus after allogeneic transplantation , 2000, British journal of haematology.
[20] H. Einsele,et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection , 2000, Bone Marrow Transplantation.
[21] J. Tarrand,et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.
[23] H. Einsele,et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. , 1993, Blood.
[24] M. Boeckh,et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. , 1992, Blood.
[25] S. Riddell,et al. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. , 1991, Blood.
[26] K. Sullivan,et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. , 1991, Seminars in hematology.